Protective effect of esculentoside A on lipopolysaccharide-induced acute lung injury in mice. 2013

Wei-ting Zhong, and Lan-xiang Jiang, and Jing-yuan Wei, and An-na Qiao, and Miao-miao Wei, and Lanan-Wassy Soromou, and Xian-xing Xie, and Xuan Zhou, and Xin-xin Ci, and Da-cheng Wang
Key Laboratory of Zoonosis, Ministry of Education, Institute of Zoonosis, College of Veterinary Medicine, Jilin University, Changchun, Jilin, PR China.

BACKGROUND Esculentoside A (EsA) is a saponin isolated from the Chinese herb Phytolacca esculenta. In our study, we sought to investigate the protective effects of EsA on lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice. METHODS To determine the effects of EsA on the reduction of histopathologic changes in mice with ALI, inflammatory cell count in bronchoalveolar lavage fluid (BALF) and lung wet-to-dry weight ratio were measured in LPS-challenged mice, and lung histopathologic changes observed via paraffin section were assessed. Next, cytokine production induced by LPS in BALF was measured by enzyme-linked immunosorbent assay. To further study the mechanism of EsA protective effects on ALI, IκBa, p38, and extracellular signal receptor-activated kinase pathways were investigated in lung tissue of mice with ALI. RESULTS In the present investigation, EsA showed marked effects by reducing inflammatory infiltration, thickening of the alveolar wall, and pulmonary congestion. Levels of tumor necrosis factor α and interleukin 6 elevated by LPS were significantly decreased in BALF in EsA-pretreated ALI model. Furthermore, EsA significantly suppressed phosphorylation of IκBa, p38, and extracellular signal receptor-activated kinase. CONCLUSIONS Taken together, our results suggest that EsA suppressed inflammatory responses in LPS-induced ALI through inhibition of the nuclear factor kappa B and mitogen activated protein kinase signaling pathways. EsA may be a promising potential preventive agent for ALI treatment.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009828 Oleanolic Acid A pentacyclic triterpene that occurs widely in many PLANTS as the free acid or the aglycone for many SAPONINS. It is biosynthesized from lupane. It can rearrange to the isomer, ursolic acid, or be oxidized to taraxasterol and amyrin. Oleanol,Hederins,Oleanane Triterpenes,Triterpenes, Oleanane
D011654 Pulmonary Edema Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening. Wet Lung,Edema, Pulmonary,Edemas, Pulmonary,Pulmonary Edemas,Lung, Wet,Lungs, Wet,Wet Lungs
D001992 Bronchoalveolar Lavage Fluid Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung. Alveolar Lavage Fluid,Bronchial Lavage Fluid,Lung Lavage Fluid,Bronchial Alveolar Lavage Fluid,Lavage Fluid, Bronchial,Lavage Fluid, Lung,Pulmonary Lavage Fluid,Alveolar Lavage Fluids,Bronchial Lavage Fluids,Bronchoalveolar Lavage Fluids,Lavage Fluid, Alveolar,Lavage Fluid, Bronchoalveolar,Lavage Fluid, Pulmonary,Lavage Fluids, Alveolar,Lavage Fluids, Bronchial,Lavage Fluids, Bronchoalveolar,Lavage Fluids, Lung,Lavage Fluids, Pulmonary,Lung Lavage Fluids,Pulmonary Lavage Fluids
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004365 Drugs, Chinese Herbal Chinese herbal or plant extracts which are used as drugs to treat diseases or promote general well-being. The concept does not include synthesized compounds manufactured in China. Chinese Herbal Drugs,Plant Extracts, Chinese,Chinese Drugs, Plant,Chinese Plant Extracts,Extracts, Chinese Plant,Herbal Drugs, Chinese
D000072000 NF-KappaB Inhibitor alpha An I-kappa B protein that inhibits the activity of dimeric NF-KAPPA B P50-REL complexes, sequesters transcription factor NF-kappaB as an inactive complex in the cytoplasm; and prevents NF-kappaB nuclear translocation and DNA binding. I Kappa B-alpha Protein,IKappaB-alpha,IKappaBalpha,Major Histocompatibility Complex Enhancer-Binding Protein MAD3,p40 Protein (IKappaB-alpha),I Kappa B alpha Protein,IKappaB alpha,Inhibitor alpha, NF-KappaB,Major Histocompatibility Complex Enhancer Binding Protein MAD3,NF KappaB Inhibitor alpha,alpha, NF-KappaB Inhibitor

Related Publications

Wei-ting Zhong, and Lan-xiang Jiang, and Jing-yuan Wei, and An-na Qiao, and Miao-miao Wei, and Lanan-Wassy Soromou, and Xian-xing Xie, and Xuan Zhou, and Xin-xin Ci, and Da-cheng Wang
May 2019, International immunopharmacology,
Wei-ting Zhong, and Lan-xiang Jiang, and Jing-yuan Wei, and An-na Qiao, and Miao-miao Wei, and Lanan-Wassy Soromou, and Xian-xing Xie, and Xuan Zhou, and Xin-xin Ci, and Da-cheng Wang
January 2014, European journal of pharmacology,
Wei-ting Zhong, and Lan-xiang Jiang, and Jing-yuan Wei, and An-na Qiao, and Miao-miao Wei, and Lanan-Wassy Soromou, and Xian-xing Xie, and Xuan Zhou, and Xin-xin Ci, and Da-cheng Wang
January 2011, Respiration; international review of thoracic diseases,
Wei-ting Zhong, and Lan-xiang Jiang, and Jing-yuan Wei, and An-na Qiao, and Miao-miao Wei, and Lanan-Wassy Soromou, and Xian-xing Xie, and Xuan Zhou, and Xin-xin Ci, and Da-cheng Wang
February 2016, Inflammation,
Wei-ting Zhong, and Lan-xiang Jiang, and Jing-yuan Wei, and An-na Qiao, and Miao-miao Wei, and Lanan-Wassy Soromou, and Xian-xing Xie, and Xuan Zhou, and Xin-xin Ci, and Da-cheng Wang
May 2013, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
Wei-ting Zhong, and Lan-xiang Jiang, and Jing-yuan Wei, and An-na Qiao, and Miao-miao Wei, and Lanan-Wassy Soromou, and Xian-xing Xie, and Xuan Zhou, and Xin-xin Ci, and Da-cheng Wang
April 2011, Pulmonary pharmacology & therapeutics,
Wei-ting Zhong, and Lan-xiang Jiang, and Jing-yuan Wei, and An-na Qiao, and Miao-miao Wei, and Lanan-Wassy Soromou, and Xian-xing Xie, and Xuan Zhou, and Xin-xin Ci, and Da-cheng Wang
December 2014, International immunopharmacology,
Wei-ting Zhong, and Lan-xiang Jiang, and Jing-yuan Wei, and An-na Qiao, and Miao-miao Wei, and Lanan-Wassy Soromou, and Xian-xing Xie, and Xuan Zhou, and Xin-xin Ci, and Da-cheng Wang
December 2012, Inflammation,
Wei-ting Zhong, and Lan-xiang Jiang, and Jing-yuan Wei, and An-na Qiao, and Miao-miao Wei, and Lanan-Wassy Soromou, and Xian-xing Xie, and Xuan Zhou, and Xin-xin Ci, and Da-cheng Wang
August 2014, Inflammation,
Wei-ting Zhong, and Lan-xiang Jiang, and Jing-yuan Wei, and An-na Qiao, and Miao-miao Wei, and Lanan-Wassy Soromou, and Xian-xing Xie, and Xuan Zhou, and Xin-xin Ci, and Da-cheng Wang
December 2009, International immunopharmacology,
Copied contents to your clipboard!